BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/6/2019 8:06:37 AM | Browse: 789 | Download: 1277
 |
Received |
|
2019-10-16 08:54 |
|
Peer-Review Started |
|
2019-10-16 08:54 |
|
To Make the First Decision |
|
2019-11-04 07:38 |
|
Return for Revision |
|
2019-11-05 02:33 |
|
Revised |
|
2019-11-10 08:13 |
|
Second Decision |
|
2019-11-22 13:19 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-11-22 22:37 |
|
Articles in Press |
|
2019-11-22 22:37 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-11-25 05:23 |
|
Typeset the Manuscript |
|
2019-12-04 07:52 |
|
Publish the Manuscript Online |
|
2019-12-06 08:06 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xue-Yang Chen, Chang-Zhou Cai, Meng-Li Yu, Ze-Min Feng, Yu-Wei Zhang, Pei-Hao Liu, Hang Zeng and Chao-Hui Yu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Chao-Hui Yu, MD, PhD, Chief Doctor, Doctor, Professor, Gastroenterology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, Zhejiang Province, China. zyyyych@zju.edu.cn |
| Key Words |
LB100; Nonalcoholic fatty liver disease; Serine/threonine-protein phosphatase 2A; Lipid metabolism; AMP-activated protein kinase α; Sirtuin 1 |
| Core Tip |
Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide, which greatly increases the medical and economic burden. We aimed to investigate the effect and underlying mechanism of LB100 in lipid accumulation during NAFLD development in mice fed a high fat diet and L02 cells treated with free fatty acids. Our study provided, for the first time, in vivo and in vitro evidence that LB100 can effectively inhibit hepatic lipogenesis via the AMPK/Sirt1 pathway and could be a therapeutic strategy for NAFLD. |
| Publish Date |
2019-12-06 08:06 |
| Citation |
Chen XY, Cai CZ, Yu ML, Feng ZM, Zhang YW, Liu PH, Zeng H, Yu CH. LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway. World J Gastroenterol 2019;25(45): 6607-6618 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i45/6607.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i45.6607 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
